All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, In the current acute myeloid leukemia (AML) treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
In the current AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
Platzbecker begins by explaining that while both the symptoms of AML and treatment for AML can cause neutropenia, increasing patients’ susceptibility to bacterial or fungal infections, antibiotic prophylaxis is not normally recommended at this stage. He highlights the lack of randomized clinical trials investigating the use of general antibiotic prophylaxis in these patients, and differentiates this from neutropenic fever when antibiotic therapy is essential.
Platzbecker goes on to discuss antifungal prophylaxis, including a randomized clinical trial that has shown benefit of posaconazole compared with current standard of care, and how posaconazole prophylaxis is therefore recommended during intensive chemotherapy in patients with neutropenia. However, he highlights the cytochrome interactions necessitating dose reductions of venetoclax or ivosidenib when antifungal agents are given, and advises caution when using these combinations.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox